MUC1 and prostate adenocarcinoma: Among 333 prostate adenocarcinomas [46], 150 metastatic PCs [47], and 107 CRPCs [48], MUC1 gene is amplified in 1.8%, 6%, and 30% of the patient cohorts, respectively (Table 3), demonstrating a unique amplification of the MUC1 gene in CRPCs.